Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Fan Y, Zhang X, Zhang Q, Zheng L, Zhou R, Sun C, Wang X, Song K, He Z, Wang H, Zhang Q, Hu W. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical Pharmacokinetics 2024, 63: 293-302. PMID: 38198010, DOI: 10.1007/s40262-023-01330-7.Peer-Reviewed Original ResearchP2X3 receptor antagonistAdverse eventsReceptor antagonistHealthy subjectsChronic coughPlacebo-controlled phase 1 trialModerate adverse eventsMost adverse eventsTwice-daily dosingSelective P2X3 receptor antagonistPhase 1 studyPhase 1 trialUnexplained chronic coughSingle oral doseStudy phaseMedian tmaxPrimary endpointGood tolerabilityOral doseTherapeutic optionsResultsA totalDrug exposureMean t1/2Lower incidenceFood intake